IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses

Immutep announced positive Phase I data for IMP761, its first-in-class LAG-3 agonist antibody, showing statistically significant and exposure-dependent inhibition of T-cell-driven immune responses in healthy volunteers. The drug was well tolerated across all seven dose levels with no serious adverse events, and the pharmacokinetic profile supports a four-week dosing interval. Multiple ascending dose study results are expected in H1 2027.